Tranexamic acid in bilateral TKA
- Conditions
- Diseases of the musculo-skeletal system and connective tissue
- Registration Number
- KCT0003849
- Lead Sponsor
- Seoul National University Bundang Hospital
- Brief Summary
The total blood loss with IA alone TXA administration in simultaneous (1062.9 ± 303.4 ml vs. 1004 ± 287.4 ml, p=0.082) and staged (908.9 ± 282.6 ml vs. 844.8 ± 277.7 ml, p=0.046) bilateral TKA patients was similar to the combined regimen in terms of clinically significant difference. The requirement of blood transfusion was also similar with both the routes of TXA administration. Furthermore, incidence of symptomatic thromboembolic events, wound complications and periprosthetic joint infection were none or extremely low without any difference between groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 619
patients with a diagnosis of primary osteoarthritis (OA) scheduled for bilateral simultaneous or staged primary TKA
exclusion criteria were patients with a diagnosis other than primary OA, severe ischemic heart disease, coagulation disorders, pre-existing hepatic or renal dysfunction, a history of thromboembolic disease and those on anticoagulation therapy
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method total blood loss and blood transfusion rate after surgery
- Secondary Outcome Measures
Name Time Method blood loss via the drain, postoperative hemoglobin drop, the proportion of patients with hemoglobin lower than 7.0, 8.0, and 9.0 g/dL, and the incidence of deep vein thrombosis (DVT), pulmonary embolism (PE) and wound complications including deep periprosthetic joint infection